¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (1ÀÏÂ÷) : 2024-05-10

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (1ÀÏÂ÷) : 2024-05-10
±³À°ÀÏÀÚ : 2024-05-10
±³À°Àå¼Ò : ¼ö¿øÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : KGOG 2024 Spring Semi-Annual Meeting (1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸

´ã´çÀÚ : ±èÇý¼÷
¿¬¶ôó : 02-512-5420

À̸ÞÀÏ : kelly.kim1436@hanmail.net

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 5 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í KGOG : Korean Gynecologic Oncology Group             »ç´Ü¹ýÀÎ ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ ¾àÀÚÀÔ´Ï´Ù.*ÇÁ·Î±×·¥¿¡ KGOG·Î µÇ¾îÀÖ´Â ºÎºÐ Âü°í ºÎŹµå¸³´Ï´Ù.


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 13:00~13:15 Data and Statistics Committee: Korean central IRB : suggestion for KGOG ÀÌ´ëÈ£(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 13:15~13:30 Data and Statistics Committee: Data management team build up experience ¾È¼Ò¿¬(ºÐ´ç¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 13:30~13:45 Establishing a foundation for activating investigator-initiated multi-center GYN cancer clinical trial group (2024' ~ 2028') ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)

Åä·Ð 05¿ù 10ÀÏ Room B 13:45~13:55 Discussion ±è±âµ¿, ÀÓÇöÁö(ºÐ´ç¼­¿ï´ëº´¿ø, ÀÏ»êÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 14:00~14:20 To understand overall global Trends in R&D 2024 and elements of Decentralized Clinical Trials(DCT): Global Trends in R&D 2024 È«Çö¼÷(IQVIA)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 14:20~14:40 Elements of Decentralized Clinical Trials and its Global Trends È«Çö¼÷(IQVIA)

Åä·Ð 05¿ù 10ÀÏ Room B 14:40~14:50 Discussion ()

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:00~14:05 KGOG 4004 (OVsurg-2102-1): A survey study of Peritonectomy (ÀÚÀ¯) ±è¸í¼±(¼ººó¼¾Æ®º´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:05~14:10 KGOG 4005 (OVsurg-2101): The analysis of the patients who have received reoperation whining 30 days after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer (ÀÚÀ¯) À¯ÇåÁ¾(¼¼Á¾Ãæ³²´ëº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:10~14:15 KGOG 4006 (OVsurg-2103): The analysis of 90-day postoperative mortality after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer (ÀÚÀ¯) ¼Û¿ëÁß(ºÎ»ê´ëº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:15~14:20 KGOG 4010 (OVsurg-2108): Assessment of QoL after LAR or visceral peritoneal stripping during cytoreductive surgery for AEOC: prospective cohort study (LAPSODY) trial (ÀÚÀ¯) ±èÈñ½Â(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:20~14:25 Lymphadenectomy In clinically early epitheLial ovArian Cancer and survival analaysis (LILAC) (ÀÚÀ¯) ½É½ÂÇõ(°Ç±¹´ëº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:25~14:30 Sentinel lymph node mapping in early stage ovarian cancer (ÀÚÀ¯) ±è´ë¿¬(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:30~14:35 OVsurg-2102-3: Total parietal peritonectomy during IDS/NACT for epithelial ovarian/fallopian tube/primary peritoneal carcinoma: A feasibility study (TPP-IDS) (ÀÚÀ¯) ÀÌÀºÁÖ(Á߾Ӵ뺴¿ø)

Åä·Ð 05¿ù 10ÀÏ Room C 14:35~14:40 Discussion ±èÀºÅÃ(°í½Å´ëÇб³)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 14:40~14:50 New Concept: OVsurg-2401 Intrathoracic approach of ovarian pleural metastasis (ÀÚÀ¯) ÀÌÁÖÇå(°æºÏ´ëº´¿ø)

Åä·Ð 05¿ù 10ÀÏ Room C 14:50~14:55 Discussion À±ÇüÁØ(ºÎ»ê´ëº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room A 15:00~15:40 Harnessing genomic insights in gynecological cancer in pursuit of improved patient outcome ¹Î°æÁø(°í´ë¾È»êº´¿ø)

Åä·Ð 05¿ù 10ÀÏ Room A 15:40~15:50 Discussion ±è¼º¹Î, À̽¹Ì(ÀÏ»êÂ÷º´¿ø, °è¸íÀǴ뵿»êÀÇ·á¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 16:00~16:10 Update of inclusion criteria discussed in the Steering Committee (ÀÚÀ¯) À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 16:10~16:25 Surgical video: da Vinci¢ç Robotic radical hysterectomy in the ROCC trial ¼ÛÀçÀ±(°í´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 16:25~16:30 Strategies for colpotomy and tumor containment: Creation of vaginal cuff and closure (ÀÚÀ¯) À̼ºÁ¾(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 16:30~16:35 Strategies for colpotomy and tumor containment: Tape (ÀÚÀ¯) ±è¼º¹Î(ÀÏ»êÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 16:35~16:40 Strategies for colpotomy and tumor containment: Stapler (ÀÚÀ¯) °øÅ¿í(¾ÆÁִ뺴¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room C 16:40~16:45 Strategies for colpotomy and tumor containment: Uterine manipulation without Lumi (ÀÚÀ¯) ¹Ú¿µÇÑ(ÇѸ²¼º½Éº´¿ø)

Åä·Ð 05¿ù 10ÀÏ Room C 16:45~16:50 Discussion ±è¹Î±Ô(»ï¼ºÃ¢¿øº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 16:00~16:10 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial (DEBULK trial) / 1. Current Status & future issues (ÀÚÀ¯) ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 16:10~16:30 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial (DEBULK trial) /2. Protocol Updates (ver. 4.0) À±º¸¼º(ÀÏ»êÂ÷º´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 16:30~16:40 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial (DEBULK trial) /3. Tips for study procedure (ÀÚÀ¯) ¹®ÁöÇö(´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸)

Åä·Ð 05¿ù 10ÀÏ Room B 16:40~16:50 Discussion °øÅ¿í, ¼³¾Ö¶õ(¾ÆÁִ뺴¿ø, °í´ë¾È¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 17:00~17:10 Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer : 1. Current Status & Dummy run study (ÀÚÀ¯) À§Âù¿ì(¿¬¼¼¾Ïº´¿ø)

±³À°½Ã°£ 05¿ù 10ÀÏ Room B 17:10~17:20 Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer: 2. Suggestion of ¡°Pattern of care study on recurrent epithelial ovarian cancer (ÀÚÀ¯) ±èº¸¶ó(ÀÌ´ë¸ñµ¿º´¿ø)

Åä·Ð 05¿ù 10ÀÏ Room B 17:20~17:30 Discussion ÀÌ¿µÀç, À±ÇüÁØ(¼¼ºê¶õ½ºº´¿ø, ºÎ»ê´ëº´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (1ÀÏÂ÷) : 2024-05-10""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³âµµ Á¦71Â÷ ´ëÇÑÁ÷¾÷ȯ°æÀÇÇÐȸ º½Çмú´ëȸ : 2024-05-10
´ÙÀ½±Û 2024³â ´ëÇѺ´¸®ÇÐȸ º½Çмú´ëȸ(1ÀÏÂ÷) : 2024-05-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
211 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/07 : 2018-09-07 0 495 2018-07-28
210 ¼­¿ï 2018³â ¼­¿ï¾Æ»êº´¿ø ¾Ïº´¿ø ½ÉÆ÷Áö¾ö : 2018-09-07 0 540 2018-07-28
209 ¼­¿ï ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ 2018³â ¹Î°£¡¤°ø°øÇù·Â(PPM) ±¹°¡°áÇÙ°ü¸®»ç¾÷ Æò°¡´ëȸ : 2018-09-07 0 613 2018-07-28
208 ´ë±¸ ±¹¸³ÀÇ·á¿ø °ø°øÀÇ·á Consensus conference(4Â÷: °æ»óÁ¦ÁÖ±Ç) : 2018-09-07 0 624 2018-07-28
207 ¼­¿ï 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-07 0 327 2018-07-28
206 ¼­¿ï °í·Á´ëÇб³¾È¾Ïº´¿ø ÀÏÂ÷ ÀÇ·áÁø°ú ÇÔ²²ÇÏ´Â ½É¹æ¼¼µ¿ÀÇ Ä¡·á : 2018-09-07 0 556 2018-07-28
205 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] ÀÇ·á»ç°í¿Í Á¶Á¤ ÁßÀç / ¼³¸íÀǹ« : 2018-09-06 0 413 2018-07-28
204 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/06 : 2018-09-06 0 377 2018-07-28
203 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-06 0 540 2018-07-28
202 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø 2018 ¾à¹°ÀÌ»ó¹ÝÀÀ ½ÉÆ÷Áö¾ö : 2018-09-05 0 963 2018-07-28
201 ¼­¿ï ±¹¸³ÀÇ·á¿ø 2018³â ½ÅÁ¾ ¹× »ý¹°Å×·¯°¨¿°º´ ´ëÀÀÀü¹®¿ä¿ø ±³À°[»çÀüµî·Ï Çʼö] : 2018-09-05 0 649 2018-07-28
200 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø »ç½Ã Áø·áÀÇ ÇÔÁ¤À» ÇÇÇØ°¡·Á¸é : 2018-09-04 0 1,077 2018-07-28
199 ¼­¿ï Á¦ÀϺ´¿ø 2018 »ý½Ä¹ß»ýµ¶¼º¿¬±¸ ¹× ¸¶´õ¸®½ºÅ©ÇÁ·Î±×·¥ÀÇ ÃֽŰæÇâ : 2018-09-02 0 741 2018-07-28
198 ±¤ÁÖ 2018 Àü³²´ëÇб³º´¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-02 0 928 2018-07-28
197 ¼­¿ï ´ëÇѺñ¸¸°Ç°­ÇÐȸ 2018 Ãß°èÇмú´ëȸ : 2018-09-02 0 981 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷